Alpha Teknova Inc. Common Stock Q3 2025 Earnings Recap

TKNO Q3 2025 November 7, 2025

Get alerts when TKNO reports next quarter

Teknova reported robust financial performance in Q3 2025, with a 9% year-over-year revenue growth driven primarily by strong sales in its Lab Essentials segment, indicating sustained operational excellence.

Earnings Per Share Beat

$-0.08 vs $-0.09 est.

+14.7% surprise

Revenue Beat

10454000 vs 9619200 est.

+8.7% surprise

Market Reaction

1-Day -2.08%

5-Day -7.9%

30-Day -8.11%

See TKNO alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue reached $10.5 million, up from $9.6 million in Q3 2024, marking the fifth consecutive quarter of growth.
Lab Essentials revenue grew 16% to $8.3 million, reflecting a healthy increase in average revenue per customer.
Clinical Solutions revenue decreased 13% to $1.7 million due to lower average revenue per customer, although customer count increased.
Operational enhancements are underway, anticipated to improve efficiency and scale revenue to over $200 million by 2026 without significant capex.
Continued focus on expanding the Clinical Solutions customer base expected to drive long-term growth through to 2026 and beyond.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit TKNO on AllInvestView.